Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus
NCT ID: NCT00580710
Last Updated: 2022-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
164 participants
OBSERVATIONAL
2001-08-31
2018-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The plan of the study is to lower the subject's blood glucose using insulin, while measuring what changes occur in brain function using what is called functional magnetic resonance imaging (fMRI).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM
NCT00575783
Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
NCT05776563
EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes
NCT00810420
Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study
NCT04283617
Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA
NCT02829593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For many people with diabetes the problem of hypoglycemia is compounded by the development of the syndrome of hypoglycemia unawareness. One aspect of hypoglycemia unawareness is impairment of the hormones normally released as blood glucose falls. Hypoglycemia triggers a release of such insulin antagonists as epinephrine, norepinephrine, glucagon, growth hormone and cortisol. These hormones act synergistically with the autonomic nervous system to raise blood glucose, counteracting insulin and restoring normoglycemia. These homeostatic mechanisms are also responsible for some of the early symptoms of low blood glucose, providing a warning to insulin-treated diabetics as glucose falls. A number of studies including research from this unit have established that strict metabolic control is associated with impairment of the normal counterregulatory response to hypoglycemia and a loss of hypoglycemia awareness.
The brain is central to the recognition of hypoglycemia and the coordination of the counterregulatory response. Neural tissue depends mainly on glucose for its energy supply. As circulating glucose falls beneath the level needed to maintain glucose transport across the blood-brain barrier, a variety of defense mechanisms are activated, including symptoms of cognitive dysfunction. However, the precise nature and causes of the adverse CNS effects of hypoglycemia are not well understood.
Functional magnetic resonance imaging (fMRI) provides a tool to measure the effects of hypoglycemia on the patterns and magnitudes of neuronal activation in the human brain, in both normal and diabetic subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventionally treated
conventionally treated, relatively poorly controlled patients with type 1 diabetes
No interventions assigned to this group
intensively treated
intensively treated, well controlled patients with type 1 diabetes
No interventions assigned to this group
lean healthy
age- and sex- matched non-diabetic, normal weight (BMI \> or = 18.5 but \< or = 25 kg/m2) control subjects
No interventions assigned to this group
obese subjects
obese individuals defined as BMI \> or = 30kg/m2
No interventions assigned to this group
type 2 diabetics
Type 2 diabetics on diet only or diet and Metformin
No interventions assigned to this group
type 1 diabetes unaware
Type 1 diabetics unaware of hypoglycemic symptoms
No interventions assigned to this group
type 1 diabetes aware
Type 1 diabetics aware of hypoglycemic symptoms
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* on a weight maintaining diet
* ability to read and speak English fluently
* Only for Type 1 Diabetics in the intensively treated group: HbA1c \< 7.5% AND documented hypoglycemia at least once per week over at least 4 weeks of frequent daily self monitoring
* Only for Type 1 Diabetics in the conventionally treated group:HbA1c ≥ 8.5%
* Age 18-40 years in the groups 1,2, and 3. Age 18-50 in groups arm 2 obese and control.
* BMI \<30 in the groups 1,2, and 3; BMI \>18.4 but \< or = 25 in the arm control group; and BMI \> or = 30kg/m2 in the obese group.
Exclusion Criteria
* History of neurologic or cardiovascular disease
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Sherwin, M.D.
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University School of Medicine
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Parikh L, Seo D, Lacadie C, Belfort-Deaguiar R, Groskreutz D, Hamza M, Dai F, Scheinost D, Sinha R, Todd Constable R, Sherwin R, Hwang JJ. Differential Resting State Connectivity Responses to Glycemic State in Type 1 Diabetes. J Clin Endocrinol Metab. 2020 Jan 1;105(1):1-13. doi: 10.1210/clinem/dgz004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0108012609
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.